Literature DB >> 32969134

Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.

Li-Ju Chen1,2, Yun-Jau Chang3,4, Yao-Jen Chang5,6.   

Abstract

This study compared the prognostic significance of staging between the American Joint Committee on Cancer 8th edition Tumor, Node, Metastasis (TNM) staging system and the Barcelona Clinic Liver Cancer (BCLC) classification in patients with hepatocellular carcinoma (HCC). The study population comprised patients with liver cancer registered in the Taiwan Cancer Database from 2007 to 2013 and was followed up until December 31, 2016. The study included patients with HCC, with known staging in both TNM and BCLC systems, and with follow-up >1 month. Primary endpoint was overall survival. Univariate and multivariate Cox proportional hazards model were constructed to investigate the significance of staging by two systems. Goodness-of-fit of model was evaluated via Akaike's information criterion (AIC), the lower the better. Among 73,136 patients with newly diagnosed liver cancer, a total of 37,062 patients with HCC (25.6% underwent surgery) were eligible. The mean age and overall survival of this cohort were 63.9 years and 27.2%, respectively. Overall survivals for stages I, II, III, and IV (the TNM system) were 54.5%, 34.9%, 10.3%, and 6.4%, respectively. Overall survivals for stages A, B, C, and D (the BCLC classification) were 54.5%, 29.2%, 9.8%, and 4.0%, respectively. The median follow-up time was 59.4 months. Multivariate Cox proportional hazards model revealed that both systems predicted overall survival, cancer-specific survival, disease-free survival, and local recurrence-free rate well. Values of ΔAIC of the BCLC classification and the TNM system were lower for the surgery group and nonsurgery group, respectively. The TNM system (8th edition) predicted long-term outcome better than the BCLC classification in patients with HCC. But in patients treated initially with surgery, the BCLC classification outperformed the 8th edition of the TNM system. IMPLICATIONS FOR PRACTICE: This work demonstrates that the Tumor, Node, Metastasis (TNM) system (8th edition) and the Barcelona Clinic Liver Cancer (BCLC) classification both predict long-term outcome significantly in patients with hepatocellular carcinoma but that the TNM system (8th edition) predicts long-term outcome better than the BCLC classification. For patients treated initially with surgery, BCLC classification outperforms in 8th edition TNM system in predicting long-term outcome. © AlphaMed Press 2020.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer classification; Hepatocellular carcinoma; Overall survival; TNM staging system

Year:  2020        PMID: 32969134      PMCID: PMC7930404          DOI: 10.1002/onco.13535

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  29 in total

1.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 2.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers.

Authors:  Yun Shin Chun; Timothy M Pawlik; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2017-07-27       Impact factor: 5.344

4.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

Authors:  Chun-Ying Wu; Yi-Ju Chen; Hsiu J Ho; Yao-Chun Hsu; Ken N Kuo; Ming-Shiang Wu; Jaw-Town Lin
Journal:  JAMA       Date:  2012-11-14       Impact factor: 56.272

5.  Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas.

Authors:  Y J Chang; K P Chung; Y J Chang; L J Chen
Journal:  Br J Surg       Date:  2016-08-23       Impact factor: 6.939

6.  Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems.

Authors:  Tomokazu Kawaoka; Hiroshi Aikata; Shintaro Takaki; Yoshimasa Hashimoto; Yoshio Katamura; Akira Hiramatsu; Koji Waki; Shoichi Takahashi; Koji Kamada; Mikiya Kitamoto; Toshio Nakanishi; Masaki Ishikawa; Masashi Hieda; Hideaki Kakizawa; Junko Tanaka; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2010-09-28       Impact factor: 4.288

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma.

Authors:  Omar Abdel-Rahman
Journal:  HPB (Oxford)       Date:  2017-09-04       Impact factor: 3.647

9.  Evaluation of eight different clinical staging systems associated with overall survival of chinese patients with hepatocellular carcinoma.

Authors:  Jian-Jun Zhao; Tao Yan; Hong Zhao; Jian-Guo Zhou; Zhen Huang; Ye-Fan Zhang; Yuan Li; Zhi-Yu Li; Xin-Yu Bi; Jian-Qiang Cai
Journal:  Chin Med J (Engl)       Date:  2015-02-05       Impact factor: 2.628

Review 10.  Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Richard A Burkhart; Timothy M Pawlik
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

View more
  4 in total

1.  Clinical and prognostic value of CT perfusion imaging parameters in patients with primary liver cancer after therapy.

Authors:  Yiming Li; Yuzhou Li; Yuan Sui; Guangyao Lin; Wenqi Huang; Yinshi Zheng
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  A Powerful Nomogram Based on the Novel D-Index to Predict Prognosis After Surgical Resection of Hepatocellular Carcinoma.

Authors:  Xia Du; Cheng-Nan Guo; Xiao-Dong Bao
Journal:  Cancer Manag Res       Date:  2021-03-17       Impact factor: 3.989

3.  Dehydrocrenatidine Induces Liver Cancer Cell Apoptosis by Suppressing JNK-Mediated Signaling.

Authors:  Bharath Kumar Velmurugan; Ming-Ju Hsieh; Chia-Chieh Lin; Hsin-Yu Ho; Ming-Chang Hsieh
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-25

4.  Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy.

Authors:  Meilong Wu; Shizhong Yang; Xiaobin Feng; Chengquan Li; Xiangchen Liu; Zhenyu Zhang; Ying Xiao; Chuchu Liu; Jiahong Dong
Journal:  J Inflamm Res       Date:  2021-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.